Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,458 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Tumors Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Spectroscopy With Surface Coils and Decoupling

NCT00581815
View directory record Official record
Conditions
Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
Interventions
Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 14, 2026, 8:17 PM EDT
Terminated Phase 1 Interventional

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

NCT00003926
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

NCT05047926
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Behavioral Counseling, Nutritional Supplement Drink, Physical Activity, Survey Administration, Computed Tomography, Biospecimen Collection, Health Education, Medical Device Usage and Evaluation
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 14, 2026, 8:17 PM EDT
Enrolling by invitation Not applicable Interventional

Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment

NCT07381985
View directory record Official record
Conditions
Hereditary Cancer Syndromes, BRCA1 Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions
Longitudinal Cancer Genetics Follow-Up Program
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 14, 2026, 8:17 PM EDT
Completed No phase listed Observational

Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer

NCT03656809
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01853644
View directory record Official record
Conditions
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
Interventions
Tivozanib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 14, 2026, 8:17 PM EDT
Not listed No phase listed Observational

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

NCT06566716
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
CleoDX ovarian cancer test
Diagnostic Test
Lead sponsor
Cleo Diagnostics Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Panama City, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer
Interventions
Bosutinib, Pemetrexed
Drug
Lead sponsor
Nagla Abdel Karim
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 14, 2026, 8:17 PM EDT
Terminated Phase 3 Interventional Results available

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

NCT03642132
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 14, 2026, 8:17 PM EDT
Completed No phase listed Observational

Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

NCT06870539
View directory record Official record
Conditions
Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 14, 2026, 8:17 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 14, 2026, 8:17 PM EDT
Terminated No phase listed Observational

Validation of a Mouse Model of Pancreatic Carcinogenesis

NCT01103128
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 1Phase 2 Interventional

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

NCT04570839
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
Interventions
COM701 in combination with BMS-986207 and nivolumab.
Drug
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

NCT00704912
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00020696
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, tirapazamine
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Intraperitoneal Hyperthermic Docetaxel

NCT00474669
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
docetaxel
Drug
Lead sponsor
University of Louisville
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 14, 2026, 8:17 PM EDT
Recruiting Not applicable Interventional

Uterine Lavage to Detect Ovarian Cancer Risk

NCT07772869
View directory record Official record
Conditions
BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Uterine Lavage, Archive Sample, Survey Administration
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 8:17 PM EDT
Recruiting No phase listed Observational

Pancreatic Cancer Genetics

NCT01102569
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Not applicable Interventional Results available

Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

NCT01826227
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal
Interventions
Positron Emission Tomography, 18F-Fluoro-2-deoxy-D-lucose, Cytoreductive surgery
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

NCT03372720
View directory record Official record
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

NCT00091273
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
incomplete Freund's adjuvant, ovarian cancer peptide vaccine, sargramostim, tetanus toxoid helper peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 14, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00217568
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 14, 2026, 8:17 PM EDT